Ovarian cancers are typically poorly immunogenic and have demonstrated disappointing responses to immune checkpoint inhibitor (ICI) therapy. Adoptive cellular therapy (ACT) offers an alternative method of harnessing the immune system that has shown promise, especially with the success of chimeric antigen receptor T-cell (CAR-T) therapy in haematologic malignancies. So far, ACT has led to modest results in the treatment of solid organ malignancies. This review explores the possibility of ACT as an effective alternative or additional treatment to current standards of care in ovarian cancer. We will highlight the potential of ACTs, such as CAR-T, T-cell receptor therapy (TCR-T), tumour-infiltrating lymphocytes (TILs) and cell-based vaccines, whilst also discussing their challenges. We will present clinical studies for these approaches in the treatment of immunologically ‘cold’ ovarian cancer and consider the rationale for future research.
卵巢癌通常免疫原性较差，对免疫检查点抑制剂（ICI）治疗的反应令人失望。过继性细胞疗法（ACT）提供了一种利用免疫系统的替代方法，已显示出前景，尤其是在嵌合抗原受体T细胞（CAR-T）疗法在血液系统恶性肿瘤中取得成功之后。迄今为止，ACT在实体器官恶性肿瘤治疗中效果有限。本综述探讨了ACT作为卵巢癌现有标准治疗的有效替代或补充治疗的可能性。我们将重点介绍CAR-T、T细胞受体疗法（TCR-T）、肿瘤浸润淋巴细胞（TILs）和细胞疫苗等ACT的潜力，同时讨论其面临的挑战。我们将介绍这些方法在治疗免疫学上“冷”的卵巢癌中的临床研究，并探讨未来研究的理论基础。
The Landscape of Adoptive Cellular Therapies in Ovarian Cancer
肿瘤(癌症)患者之家